Last reviewed · How we verify
Descovy or Truvada
Descovy and Truvada are antiretroviral combinations that inhibit HIV reverse transcriptase and integrase to prevent viral replication and transmission.
Descovy and Truvada are antiretroviral combinations that inhibit HIV reverse transcriptase and integrase to prevent viral replication and transmission. Used for HIV-1 infection treatment (in combination with other antiretrovirals), Pre-exposure prophylaxis (PrEP) for HIV-1 prevention in high-risk individuals.
At a glance
| Generic name | Descovy or Truvada |
|---|---|
| Sponsor | Brigham and Women's Hospital |
| Drug class | Nucleoside/nucleotide reverse transcriptase inhibitor combination |
| Target | HIV reverse transcriptase, HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Descovy contains tenofovir alafenamide (TAF) and emtricitabine (FTC), while Truvada contains tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). Both are nucleoside/nucleotide reverse transcriptase inhibitors that block HIV's ability to copy its genetic material and integrate into host cells. These drugs are used for both treatment of HIV infection and pre-exposure prophylaxis (PrEP) to prevent infection in high-risk individuals.
Approved indications
- HIV-1 infection treatment (in combination with other antiretrovirals)
- Pre-exposure prophylaxis (PrEP) for HIV-1 prevention in high-risk individuals
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Renal impairment (TDF-based formulations)
- Bone density loss (TDF-based formulations)
Key clinical trials
- Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1 (PHASE2, PHASE3)
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE: A Multi-Center, Single-Arm, Open-Label, Phase 4 Study Assessing the Safety and Efficacy of B/F/TAF in HIV-Positive Adults Returning to Care After Experiencing a Treatment Interruption of ≥12 Weeks (PHASE4)
- Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study of GS-3242 in Participants With HIV-1; Substudy-05 (PHASE1)
- UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children (PHASE2)
- Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Descovy or Truvada CI brief — competitive landscape report
- Descovy or Truvada updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI